Four Finalists Selected for BioWest 2010 Venture Showcase Competition, Presenting Life-Changing Technologies

Share Article

Cutting-edge development of a universal influenza vaccine, creation of an innovative hybridCpeptide manufacturing process, groundbreaking wastewater treatment through a new algae production system, and a revolutionary nontoxic surface treatment to control the growth of bacteria in hospitals, comprise the four finalists in this year's BioWest Venture Showcase competition.

Cutting-edge development of a universal influenza vaccine, an innovative hybrid peptide manufacturing process, groundbreaking algae production system for wastewater treatment, and a revolutionary nontoxic surface treatment to control the growth of bacteria comprise the four finalists in this year's BioWest Venture Showcase competition sponsored by Dorsey & Whitney and the Metro Denver Economic Development Corporation. The announcement is made by Holli Baumunk, President and CEO, Colorado BioScience Association (CBSA).

"By focusing on new therapies and vaccines targeting common diseases, creating systems and devices to fix problems and finding ways to more easily treat wastewater, the four finalists chosen for this year's BioWest Venture Showcase are all on the frontline in making the world a better place," Baumunk says. "The four finalists were selected from a group of 19 that will present at the BioWest Venture Showcase on Wednesday, September 29 from 1:00-2:30 p.m. at Denver's Grand Hyatt. The winner will receive the $7,500 Dorsey & Whitney Venture Showcase award at the CBSA's Annual Awards Dinner on the same day," Baumunk says.

To attend the Venture Showcase presentations and Annual Awards Dinner at BioWest, visit

An overview of each finalist follows: 

  • AmideBio (Boulder, CO) is a company in the business of improvement of human health by providing low cost and efficient manufacturing of peptides for the research and development markets. The Company's proprietary hybrid manufacturing process also enables small scale cGMP manufacturing for clinical trials and the development of generic peptide therapeutics. In order to make progress against certain diseases and conditions, such as Alzheimer's, it is necessary to be able to cost-effectively produce large quantities of peptides for research and development use, and ultimately therapeutic purposes. Visit,
  • BioVantage: (Golden, CO) In response to escalating water scarcity and the undeniable water/energy nexus, BioVantage is developing cost-effective, sustainable, "green" solutions for wastewater reclamation. Comprised of patent-pending technology and processes, BioVantage's algae production system produces proprietary algae consortia for use in wastewater lagoons to accelerate natural remediation. This allows a greater degree of reuse of one of our planet's most valuable and scarce resources, water. Visit,
  • PeptiVir, Inc. (Aurora, CO) is an early stage biopharmaceutical company focused on the development and commercialization of a conformationally-constrained, synthetic peptide-based vaccine platform for the prevention of viral diseases. PeptiVir's lead product, PVI-1000, has the potential to be a "universal" influenza vaccine wherein one or two administrations could lead to sustained protection against multiple seasonal and pandemic strains. This is in contrast to existing influenza vaccines that must be generated and administered yearly and induce antibodies that provide protection only against that year's seasonal flu strains.
  • Sharklet Technologies, Inc. (Aurora, CO) is a life sciences company that has engineered a revolutionary surface product called Sharklet. Sharklet is the first non-toxic, long-lasting and no-kill surface used to control the growth of bacteria. Sharklet is a patented surface technology comprised of millions of raised, microscopic features arranged in distinct diamond shapes to form a continuous pattern. Laboratory tests show that the Sharklet micro-pattern disrupts several critical microbial colonizing processes that are necessary for bacteria to develop into a disease-causing biofilm. In tests simulating an ambient hospital environment, the Sharklet patterned surface has shown to significantly reduce survival and touch transfer of bacteria. Visit,

About Colorado BioScience Association

The CBSA supports the economic development of Colorado through the creation of a premier bioscience cluster within the state. Representing more than 400 members, the CBSA facilitates growth of the bioscience industry in Colorado through advocacy, representation and service. Visit
CBSA also is found on these social media sites:
News Feed:
LinkedIn Group:
Facebook Fan Page:
YouTube Channel:
About Dorsey & Whitney LLP
Dorsey is a business law firm applying a business perspective to our clients' needs and committing to help our clients maintain that competitive edge. Dorsey's corporate lawyers serve clients ranging from start-ups to multinational corporations in a variety of matters including financings, M&A and joint ventures, regulatory, and general corporate matters.  Dorsey represents numerous medical device, healthcare and other technology companies. 
About Metro Denver Economic Development Corporation
The Metro Denver Economic Development Corporation (Metro Denver EDC), an affiliate of the Denver Metro Chamber of Commerce, is the nation's first and only truly regional economic development entity in which many area economic development groups have joined together to represent, and further, the interests of an entire region.. Visit:


Leah Kientz, Director, Public Policy & Programs, Colorado BioScience Association 303-592-4088

Maggie Chamberlin Holben, APR, Absolutely Public Relations - - 303-984-9801


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website